Cancer

Title
High-dose Busulfan and Melphalan followed by Bortezomib (BuMelVel) as Chemotherapy prior to Autologous Stem Cell Transplantation for Multiple Myeloma
Trial Number
202930091510
Number of Participants
25
Principal Investigator

Tulio Rodriguez

M.D.
Hematology/Oncology
Associate Professor
Eligibility

Participants must be greater than or equal to 18 years of age.

Patients must have been diagnosed with multiple myeloma and must have undergone successful pre-transplant work-up.

Response criteria will be assessed according to the International Myeloma Working Group uniform response criteria for multiple myeloma.

Purpose

The purpose of this study is to evaluate the effectiveness of high-dose busulfan and melphalan followed by bortezomib as chemotherapy prior to autologous stem cell transplantation for individuals with multiple myeloma and to measure the level of cells in the blood in order to evaluate disease response.

Enrollment

(708) 327-3157

MORE CLINICAL TRIALS

Clinical Trials

For more information call (888) LUHS-888.